Samarium for osteoblastic bone metastases and osteosarcoma

被引：34
作者：
Anderson, Pete [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 11期
关键词：
153Sm-EDTMP; bone cancer; bone metastases; bone scan; breast cancer; MIMvista fusion imaging software; osteosarcoma; prostate cancer; skeletal neoplasia; radiation therapy; radiopharmaceutical; radiosensitisation; sarnarium-153; lexidronam;
D O I：
10.1517/14656566.7.11.1475
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Samarium-153 lexidronam (Sm-153-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. Sm-153-EDTMP decay has a therapeutic p-emission and ay-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. Sm-153-EDTMP targets multiple sites of disease, with a single administration. Side effects of Sm-153-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose Sm-153-EDTMP treatment of cancer involving bone.
引用
收藏
页码：1475 / 1486
页数：12
相关论文
共 107 条
[1]  
Aas M, 1999, CLIN CANCER RES, V5, p3148S
[2]   Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone [J].
Alberts, AS ;
Smit, BJ ;
Louw, WKA ;
vanRensburg, AJ ;
vanBeek, A ;
Kritzinger, V ;
Nel, JS .
RADIOTHERAPY AND ONCOLOGY, 1997, 43 (02) :175-179
[3]  
ANDERSON P, 2005, PEDIAT BLOOD CA 1003
[4]   Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma [J].
Anderson, PM ;
Wiseman, GA ;
Erlandson, L ;
Rodriguez, V ;
Trotz, B ;
Dubansky, SA ;
Albritton, K .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6895-6900
[5]   High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases [J].
Anderson, PM ;
Wiseman, GA ;
Dispenzieri, A ;
Arndt, CAS ;
Hartmann, LC ;
Smithson, WA ;
Mullan, BP ;
Bruland, OS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :189-196
[6]  
[Anonymous], 1997, MED LETT DRUGS THER, V39, P83
[7]  
Applebaum FR, 1988, ANTIBODY IMMUNOCONJ, V1, P263
[8]  
Atkins H L, 1996, Q J Nucl Med, V40, P285
[9]  
ATKINS HL, 1995, J NUCL MED, V36, P725
[10]   Targeting of therapeutic agents to bone to treat metastatic cancer [J].
Bagi, CM .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (07) :995-1010
12345678910